We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Evaluating the Cost-Effectiveness of Celecoxib versus Ibuprofen and Naproxen in Patients with Osteoarthritis in United Arab Emirates Based on the PRECISION Trial.
- Authors
Chirikov, Viktor V; Walker, Chris; Stephens, Jennifer M; Schepman, Patricia; Chambers, Richard; Bakir, Mahmoud; Poorman, Gregory W; Haider, Seema; Farghaly, Mohammed
- Abstract
aims (2018). Median monthly drug costs were derived from UAE Ministry of Health and Prevention's published prices ($26.98 celecoxib; $20.25 ibuprofen; $20.50 naproxen). Health utility and excess mortality associated with toxicities were sourced from the literature. The willingness-to-pay thresholds used were 1 and 3 GDP per capita ($40,000–$120,000). Results: The total average cost per patient was $812.88 for celecoxib, $775.26 for ibuprofen, and $731.17 for naproxen while cost components attributed to toxicities were lowest with celecoxib ($360.26, $438.31, and $388.60, respectively). Patients on celecoxib had more QALYs (1.339), compared with ibuprofen (1.335) and naproxen (1.337), resulting in an incremental cost-effectiveness ratio of $11,502/QALY gained for celecoxib versus ibuprofen and $39,779 for celecoxib versus naproxen. Probabilistic sensitivity analyses demonstrated celecoxib to be 81% cost-effective versus ibuprofen and 50% versus naproxen at $40,000/QALY. The most influential model parameters were MACE relative safety and drug costs. Conclusion: From UAE third payer perspective, celecoxib is a long-term cost-effective treatment for osteoarthritis patients when compared with ibuprofen, and equally likely as naproxen to be cost-effective. With the expected increasing burden of chronic diseases in the Gulf region, study findings can inform decisions regarding the cost-effective pain management of osteoarthritis in UAE. Clinicaltrials.gov Registration Number: NCT00346216.
- Subjects
UNITED Arab Emirates; PERSIAN Gulf; CELECOXIB; NAPROXEN; IBUPROFEN; OSTEOARTHRITIS; COST effectiveness
- Publication
ClinicoEconomics & Outcomes Research, 2021, Vol 13, p409
- ISSN
1178-6981
- Publication type
Article
- DOI
10.2147/CEOR.S280556